Miruvor
Sign up
The short answer

What studies of Azelastine (Astepro) found

1paper on Azelastine (Astepro)
60people in 1 study testing Azelastine (Astepro) alone
1randomised trial, the strongest kind of study

If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 1 paper.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Smell and taste loss1 study · 60 people took Azelastine (Astepro) Uncertain –
Very low certainty

Why this grade: Uncertain, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (207 in all); helped less than group i (g1), an active treatment; not a sign of harm.

The placebo trial240 randomised · 207 analysed · 3 weeks · 125 µg/50 µg/25 mL actuation nasal spray, one puff in each nostril twice daily

Smell and taste loss improved less than with the comparison treatment.

Azelastine (Astepro) helped smell and taste loss less than group i (g1) in the one comparison. Uncertain · very low certainty –

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (207 in all)
  • Helped less than group i (g1), an active treatment; not a sign of harm
See the 1 study
  1. Study of Different Local Treatments of Post COVID-19 Smell Dysfunction. (2022)

    People in the study
    240 randomised · 207 analysed
    Dose
    125 µg/50 µg/25 mL actuation nasal spray, one puff in each nostril twice daily
    Outcome
    butanol threshold test
    Effect
    worse
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    High

Side effects

No study of this treatment alone reported side effects we could read.

All papers

  1. Study of Different Local Treatments of Post COVID-19 Smell Dysfunction.2022 · placebo trial · 240 randomised · 207 analysed

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime